Published online 10 May 2008
Haematologica, Vol 93, Issue 6, 834-841 doi:10.3324/haematol.11277
Copyright © 2008 by Ferrata Storti Foundation
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission
Loic Fouillard1,
Myriam Labopin2,
Alois Gratwohl3,
Eliane Gluckman4,
Francesco Frassoni5,
Dietrich W. Beelen6,
Roelof Willemze7,
Emili Montserrat8,
Didier Blaise9,
Arturo Iriondo Atienza10,
Jorge Sierra11,
Moema Santos4,
Norbert-Claude Gorin1,2,
Vanderson Rocha2,4 on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation*
1 Hôpital Saint-Antoine AP-HP, Paris, France;
2 AP-HP Saint-Antoine and University Pierre et Marie Curie-Paris 6, Paris, France;
3 University Hospital, Basel, Switzerland;
4 Hôpital Saint-Louis AP-HP, Paris, France;
5 Ospedale San Martino, Genova, Italy;
6 University Hospital, Essen, Germany;
7 Leiden University Hospital, Leiden, Netherlands;
8 Hospital Clinic, Barcelona, Spain;
9 Institut Paoli Calmettes, Marseille, France;
10 Hospital U. Marqués de Valdecilla, Santander, Spain and
11 Hospital Santa Creu i San Pau, Barcelona, Spain
Correspondence: Loic Foullard, Department of Hematology, Hopital Saint-Antoine, AP-HP, 184 Rue du Faubourg Saint- Antoine, 75012 Paris, France. E-mail:loic.fouillard{at}sat.ap-hopparis. fr
 |
ABSTRACT
|
|---|
Background: The possibility of performing syngeneic hematopoietic stem cell transplantation is rare and there are concerns about the absence of a graft-versus-leukemia effect following such a strategy. We report the outcomes of a large series of adult patients who underwent syngeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia or acute lymphoblastic leukemia.
Design and Methods: The outcomes of all syngeneic transplants for acute myeloblastic or lymphoblastic leukemia reported to the European Group for Blood and Marrow Transplantation registry were analyzed; a study of prognostic factors was performed for those transplanted in first complete remission.
Results: One hundred and sixty-two patients, 109 with acute myeloblastic leukemia and 53 with acute lymphoblastic leukemia, were identified; 116 were in first complete remission. Most of the patients did not receive prophylaxis against graft-versus-host disease. Nineteen patients developed acute graft-versus-host disease and only three patients developed chronic graft-versus-host disease. The median follow-up was 60 months. At 5 years the non-relapse mortality was 8±5%, the relapse incidence 49±8% and the leukemia-free survival 43±3%. The corresponding figures for patients in first complete remission were 7±2%, 40±4% and 53±5% at 5 years. Analysis of patients in first complete remission showed that the number of courses of chemotherapy required to induce first complete remission was the main risk factor: the leukemia-free survival at 5 years was 66±6% when first complete remission was reached after one induction course of chemotherapy and was only 20±9% when first complete remission was reached after at least two induction courses of chemotherapy (p=0.0001); the relapse incidence was 30±6% and 54±10%, respectively (p=0.007).
Conclusions: Outcomes were better for patients transplanted in first complete remission than in second complete remission or a more advanced phase of the disease. When a syngeneic donor is available for patients with high risk acute leukemia, allotransplantation should be performed as soon as the first complete remission has been achieved, ideally with one course of chemotherapy.
Key words: acute leukemia, syngeneic transplantation.
|
Introduction
|
|---|
Treatment of acute leukemia includes allogeneic hematopoietic stem cell transplantation (HSCT) from a family member or an unrelated donor. The possibility of performing HSCT from an identical twin donor, i.e., a syngeneic donor, is rare. Indeed the last 2005 activity survey of the European Group for Blood and Marrow Transplantation (EBMT) on HSCT indicated that, of a total of 8890 allogeneic transplants, 4702 were done from a related HLA identical donor, 514 from a related HLA non-identical donor, 3617 from an unrelated donor and only 57 (0.64%) from a twin donor.1 It was previously reported that syngeneic HSCT was associated with a low non-relapse mortality but with a high relapse incidence.2,3 This was corroborated by an International Bone Marrow Transplantation Registry (IBMTR) comparative study showing that after allogeneic bone marrow transplantation for early leukemia the highest relapse incidence was observed after syngeneic transplants and the lowest after unmanipulated bone marrow transplants when graft-versus-host disease (GVHD) was diagnosed. 4 These observations were the demonstration of an immunological effect after allogeneic bone marrow transplants but were not in favor of a possible graft-versus- leukemia effect after syngeneic HSCT. However, proven GVHD is observed after approximately 10% of syngeneic HSCT, indicating that a syngeneic graft-versus-leukemia effect may exist. Indeed, efforts have been made to identify factors that could influence the occurrence of a syngeneic graft-versus-leukemia effect such as nucleated cell dose in the graft5 and parity.6
In this study we report the largest series of syngeneic HSCT for acute myeloblastic leukemia (AML) and lymphoblastic leukemia (ALL) in adults, all reported to the EBMT registry by European teams.
|
Design and Methods
|
|---|
Patients
Adult patients (over 16 years old) undergoing HSCT from a syngeneic identical twin for AML or ALL were selected from the Acute Leukaemia Working Party registry of the EBMT over a period of 30 years from January 1975 to December 2003 (median year: 1994); 72% of patients were transplanted after January 1990. The selected patients were reported to the EBMT by 86 European teams. All patients had de novo acute leukemia. A total of 162 eligible patients who received a syngeneic HSCT were selected for the study. All patients received a myeloablative conditioning regimen.
Statistical analysis and end-points
A descriptive analysis was performed for all patients and patients transplanted in first complete remission. Prognostic analyses were restricted to the subgroup of adult patients transplanted in first complete remission, constituting the only homogeneous subgroup with a number of patients (n=116) sufficient for a multivariate analysis.
The primary end-point of the study was to determine the outcome defined as time to death or relapse, non-relapse mortality and leukemia-free survival. Variables considered were recipient age, sex, disease characteristics (type of leukemia, cytogenetics, white blood cell count at diagnosis, cytomegalovirus serology), donor characteristics (cytomegalovirus serology), time from diagnosis to first remission, number of induction courses to reach first remission, disease status at transplant (first complete remission, second complete remission or more advanced disease); transplant characteristics (source of stem cells, dose of nucleated cells infused, conditioning regimen including total body irradiation or not, GVHD prophylaxis and year of transplant)
Cumulative incidence curves were used in a competing risk setting, since death and relapse are competing events.7 Probabilities of leukemia-free survival were calculated using the Kaplan-Meier estimate; the log-rank test was used for univariate comparisons.
In the population of patients allografted in first remission, associations of graft characteristics with outcomes were evaluated in multivariate analyses, using Cox proportional hazards for leukemia-free survival and survival, and the proportional sub-distribution hazard regression model of Fine and Gray for other outcomes.8 A stepwise backward procedure was used to construct a set of independent predictors for each end-point. All predictors with a p value below 0.10 were considered, and sequentially removed if the p value in the multiple model was above 0.05. All tests were two-sided. The type I error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS (Inc., Chicago) and Splus (MathSoft, Inc, Seattle) software packages.
|
Results
|
|---|
Disease and patient characteristics
Table 1 lists the disease, patient and transplant characteristics. Overall 162 patients were analyzed: 109 with AML and 53 with ALL. The median age of the whole population was 36 years old (range, 16–68 years old). One hundred and sixteen patients were transplanted in first complete remission, 21 in second complete remission and 25 in a more advanced stage of disease. Information on cytogenetics at diagnosis was available for 78/162 patients comprising 59 with AML and 25 with ALL. According to the South-Western Oncology Group (SWOG) classification,9 eight AML patients were in the favorable prognostic group, 47 patients were in the intermediate group and four patients were in the unfavorable group. Among the ALL group no abnormality was observed in 16 patients, whereas cytogenetic abnormalities were reported for nine patients: two patients with t(4;11) and seven with t(9;22). One patient had a detectable bcr-abl transcript fusion without a detectable t(9;22).
Disease and patient characteristics of patients with acute leukemia transplanted in first complete remission
One hundred and sixteen patients were transplanted in first complete remission. Table 1 lists the disease, patient and transplant characteristics. Eighty-two patients had AML and 34 ALL. The median age was 36 years old (range, 16–62 years old). The median time from diagnosis to first complete remission was 43 days (range, 14–196), the median time from first complete remission to transplantation 107 days (range, 13–321 days) and the median time from diagnosis to transplantation 162 days (range, 49–358 days). The number of lines of induction chemotherapy to reach first complete remission was one for 68% of the patients, two for 21% of patients, and over two for 11% of the patients. Seven patients received a syngeneic transplant more than 6 months after achieving first complete remission.
Transplant characteristics of all patients
All patients received a myeloablative conditioning regimen which included total body irradiation in 58% of the patients overall, in 49% of those with AML and in 79% of the ALL patients. The source of stem cells was bone marrow for 70% of the patients, peripheral blood for 29%, and 1% received both bone marrow and peripheral blood. The majority of patients (86.5%) did not receive any GVHD prophylaxis, whereas the remaining (13.5%) did receive prophylaxis. Information on parity of female patients and recipients was partially retrieved (62.5% of syngeneic transplantations). Twenty-two female patients were nulliparous and 21 parous, 19 female donors were nulliparous and 20 parous.
Transplant characteristics of patients transplanted in first complete remission
All patients received a myeloablative conditioning regimen, which included total body irradiation in 58% of them. The source of stem cells was bone marrow for 68% of the patients. No GVHD prophylaxis was given to 84.5% of this group of patients. Serology for cytomegalovirus was negative for both donor and recipient in 31% of the transplants.
Engraftment
Engraftment was defined as the time to reach a neutrophil count of 0.5x109/L and a platelet count of 0.5x109/L. All patients but one engrafted. For bone marrow transplantation the median time to reach 0.5x109/L neutrophils, calculated from the day of the transplant, was 15 days (range, 10–51 days) and the median time to reach a platelet count of 0.5x109/L was 24 days (range, 12–247 days). For peripheral blood transplantation the median time to reach neutrophil engraftment was 12 days (range, 8–42 days), and the time to reach a platelet count of 0.5x109/L was 16 days (range, 8–73 days).
Acute and chronic GVHD
Nineteen patients developed acute GVHD: 13 grade I, four grade II, and two grade III-IV. For six patients the diagnosis of acute GVHD was proven by a biopsy; five of these six patients were confirmed to be monozygotic twins either serologically (n=3) or by molecular biology (n=2). Eight patients out of 22 patients given GVHD prophylaxis developed acute GVHD. Only three patients developed chronic GVHD which was limited in two patients and extensive in one patient. One patient died from acute GVHD.
Outcome
The median follow-up for survivors was 60 months (range 1–275 months). A total of 69/162 patients died. The original disease was the cause of death for 49 patients. The remaining 20 patients died from GVHD (n=1), cardiac toxicity (n=2), hemorrhages (n=2), graft failure (n=1), infections (n=6), interstitial pneumonitis (n=4), secondary malignancy (n=1), and other non-relapse- related causes (n=3). The outcome at 5 years for all patients showed a leukemia-free survival of 43±3%, a relapse incidence of 49±8% and a non-relapse mortality rate of 8±5%. Patients in first complete remission showed leukemia-free survival, relapse incidence and non-relapse mortality rates at 5 years of 53±5%, 40±4% and 7±2%, respectively (Figure 1). At 1 year the leukemia-free survival was 40±45% and 42±17% for patients with AML (n=10) or ALL (n=11), respectively, transplanted in second complete remission. At 3 years the leukemia-free survival, relapse incidence and non-relapse mortality rates in the whole group of patients transplanted in second complete remission were 28±11%, 62±10% and 10±7%, respectively, and the corresponding figures in patients transplanted in a more advanced stage of disease were 27±9%, 69±7% and 4±4% at 3 years.
View larger version (31K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1. Leukemia-free survival, relapse incidence and nonrelapse mortality of patients with acute leukemia after syngeneic hematopoietic stem cell transplantation in first complete remission. (A) Leukemia-free survival probability. The percentage shown is the 5-year probability. (B) Relapse incidence (RI) and non-relapse mortality (NRM) probability. The percentage shown are for the 5- year timepoint.
|
|
Outcome of patients with Philadelphia-positive ALL transplanted in first complete remission
The t(9; 22) Philadelphia chromosome was detected, by cytogenetics, in five patients and one further patient had the bcr/abl rearrangement detected by molecular biology, with a normal karyotype. Of these six paients, two died from relapse at 865 days and 778 days after transplantation. The remaining four patients were alive, one in relapse with a follow-up of 234 days, and the three in complete remission with followups of 636 days, 632 days and 138 days.
Analyses of risk factors associated with outcomes after syngeneic HSCT for patients with acute leukemia transplanted in first complete remission
Cytomegalovirus status, source of stem cells, year of transplant, type of acute leukemia (AML or ALL), and total body irradiation in the conditioning regimen were not statistically significantly associated with outcomes (Table 2). The numbers of courses of chemotherapy to induce first complete remission was an important factor associated with leukemia-free survival, relapse incidence and non-relapse mortality. Leukemia-free survival at 5 years was 66±6% when first complete remission was reached after one course of induction chemotherapy and was only 20±9% when first complete remission was reached after at least two courses of induction chemotherapy (p=0.0001). The relapse incidence was 30±6% and 64±10%, respectively (p=0.007), and the non-relapse mortality rate 4±3% and 15±8%, respectively (p=0.052) (Figure 2). Recipient age (below 36 years old) was also associated with increased leukemia-free survival.
View larger version (54K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2. Leukemia-free survival, relapse incidence and nonrelapse mortality of patients with acute leukemia after syngeneic hematopoietic stem cell transplantation during first complete remission (CR1) according to the number of induction chemotherapy courses needed to reach CR1. (A) Leukemia-free survival. Upper curve: one induction course to reach CR1. Lower curve: more than one induction course to reach CR1. The percentages shown are for the 5-year timepoint. (B) Relapse incidence. Lower curve: one induction course to reach CR1. Upper curve: more than one induction course to reach CR1. The percentages shown are for the 5-year timepoint. (C) Non-relapse mortality. Lower curve: one induction course to reach CR1. Upper curve: more than one induction course to reach CR1. The percentages shown are for the 5-year timepoint.
|
|
In multivariate analysis the only variable that was still statistically significant was one induction course of chemotherapy to reach first complete remission. This variable was associated with a higher leukemia-free survival (p=0.0007, RR: 0.33, 95% CI: 0.18–0.63) and a lower relapse incidence (p=0.015, RR: 2.4, 95% CI: 1.2–4.8).
|
Discussion
|
|---|
Syngeneic HSCT is a rare event. We report here the largest series of syngeneic transplants performed for acute leukemia in adults. The objectives of this study were to describe the outcomes of patients receiving such transplants and to analyze prognostic factors in adult patients who underwent syngeneic HSCT in first complete remission.
We found that leukemia-free survival at 5 years was 53% for patients transplanted in first complete remission, and 66% when the first complete remission was obtained after one induction course. These results are comparable to those previously reported after genoidentical HSCT for acute leukemia with leukemia free survival being 48% at 5 years and 66% at 3 years,10,11,12 and those reported in the last EBMT survey on acute leukemia (www.ebmt.org) which showed that adult patients transplanted with a graft from an HLA identical donor had an overall survival at 5 years of 57% when transplanted in first complete remission (n=8549), 41% when transplanted in second complete remission (n=2046) and 18% when transplanted in a more advanced stage of disease (n=3202). These survival rates are essentially the same as those in our study. This is mainly explained by the very low non-relapse mortality usually found after syngeneic HSCT. However we also found that the relapse incidence at 5 years was only 40% among patients transplanted in first complete remission and only 30% when the first complete remission was reached with one induction course. This last observation indicates that the combination of a low non-relapse mortality rate and a possible syngeneic graft-versus-leukemia effect resulted in a good survival. Indeed, a syngeneic graft-versus-leukemia effect has already been suggested by retrospective studies comparing syngeneic HSCT to HLA-identical sibling HSCT in acute leukemia, chronic myeloid leukemia3 and multiple myeloma.13 In these studies the leukemia-free survival of patients given the two types of transplants was not statistically different. Furthermore authentic cases of acute and chronic GVHD were reported after syngeneic transplants.14–16 In our study, acute GVHD occurred in only 19 patients (11%) and chronic GVHD in only three patients (1.8%). Acute GVHD was histologically proven in six patients who were all, except one, confirmed as monozygotic twins, thus excluding the possiblity that the GVHD had occured in non-twin transplants. Given the low incidence of acute and chronic GVHD in our study, it was not possible to analyze any associations of GVHD with outcomes, particulary relapse.
Some authors have tried to identify parameters that could influence the occurrence of GVHD and the graft-versus-leukemia effect after syngeneic HSCT. In an IBMTR study the dose of syngeneic nucleated cells infused was shown to have an effect on survival.5 The outcome was improved when more than 3x108 nucleated cells/kg were transplanted: a lower relapse rate was associated with a higher dose of nucleated cells.
A more recent study identified risk factors for GVHD in 126 consecutive cases of syngeneic HSCT.6 In this study the cumulative incidence of GVHD was 18%. GVHD was more frequent when the donor was parous than when the donor was nulliparous or male, and when the recipient was parous than when the recipient was nulliparous. Other risk factors for syngeneic GVHD included age, busulfan/melphalan/thiotepa in the conditioning regimen, post-transplant interleukin 2, HLA-A26, and more recent transplantation year. However, it was pointed out that many of the risk factors in syngeneic GVHD were the same as those in allogeneic HSCT. In our study the main prognostic factor that influenced outcome, according to both univariate and multivariate analyses, was the number of induction courses to reach first complete remission. This factor has already been recognized as a major prognostic factor in all transplants for acute leukemia.17,18 Neither our study nor previous studies have been able to identify peculiar factors that could influence the occurrence of syngeneic GVHD and a syngeneic graft-versus-leukemia effect.
In summary, this study showed that syngeneic HSCT for acute leukemia can lead to a high survival rate among adult patients transplanted in first complete remission. This was mainly due to a low non-relapse mortality rate but also to a possible syngeneic graft-versus-leukemia effect. Since the results of syngeneic transplantation were better when the transplant was performed in first complete remission obtained after one course of induction, it remains questionable whether a search for an alternative donor is necessary in other patients.
|
Appendix
|
|---|
Leiden University Hospital, BMT Center Leiden, Leiden, Netherlands. Medizinische Klinik und Poliklinik, Abteilung Innere Medizin III, Ulm, Germany. Rigshospitalet, BMT Unit Dept. of Hematology L 4042, Copenhagen, Denmark. Hopital St. Louis, Dept.of Hematology - BMT, Paris, France. University Hospital, Dept. of Medicine, Zürich, Switzerland. University Hospital Gasthuisberg, Dept. of Hematology, Leuven, Belgium. Karolinska University Hospital, Huddinge Haematology Center, Huddinge, Sweden. Hopital Saint Antoine, Dept. of Hematology, Paris, France. Hospital Clinic, Institute of Hematology & Oncology, Dept. of Hematology, Barcelona, Spain. Institut Jules Bordet, Experimental Hematology, Brussels, Belgium. Royal Free Hospital and School of Medicine, Dept. of Haematology, London, United Kingdom. Ospedale San Martino, Dept. of Hematology, Genoa, Italy. Royal Marsden Hospital, Leukaemia Myeloma Units, London, United Kingdom. University College London Hospital, Dept. of Haematology, London, United Kingdom. Medizinische Universitaet Wien, Klinik fuer Innere Medizin I, Knochenmarktransplantation, Vienna, Austria. Unité de Transplantation et de Thérapie Cellulaire, Inserm UMR 599, Institut Paoli Calmettes, Marseille, France. Azienda Ospedaliera S. Giovanni, Centro Trapianti Midollo, U.O.A. Ematologia, Turin, Italy. Univ.’La Sapienza’, Dip. Biotecnologie Cellulari ed Ematologia, Rome, Italy. Cliniques Universitaires St. Luc, Dept. of Haematology, Brussels, Belgium. Rikshospitalet, Dept. of Medicine, The National Hospital, Oslo, Norway. Hospital de la Princesa, Department of Hematology, Madrid, Spain. Radboud University - Nijmegen Medical Center, Department of Haematology, Nijmegen, Netherlands. University Medical Center, Dept. of Haematology, Utrecht, Netherlands. Bologna University, S.Orsola-Malpighi Hospital, Institute of Hematology & Medical, Oncology L & A Seràgnoli, Bologna, Italy. Hospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain. Glasgow Royal Infirmary, Bone Marrow Transplant Unit, Glasgow, United Kingdom Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, Netherlands. Academisch Ziekenhuis bij de Universiteit, Emma Kinderziekenhuis, Amsterdam, Netherlands. Ospedale Civile, Dept. of Hematology, Pescara, Italy. Hôpital Henri Mondor, Sve d’ Hematologie, Creteil, France. St James University Hospital, Blood and Bone Marrow Transplant Center, Leeds, United Kingdom. KSH, Campus Kiel, Division of Stem Cell and Immunotherapy, 2. Medical Dept., Kiel, Germany. University Hospital, Dept. of Bone Marrow Transplantation, Essen, Germany. Hopitaux Universitaires de Geneve, Departement Medecine Interne, Geneva, Switzerland. Hopital La Miletrie, Bone Marrow Transplant Unit, Clinical Hematology, Poitiers, France CHU Bordeaux, Hôpital Haut-leveque, Pessac, France. Fédération de Greffe de Moelle et de Thérapie Cellulaire d’Auvergne, Center Jean Perrin-CHU Clermont-Ferrand, Clermont-Ferrand, France. Hopital Claude Huriez, Service de Maladies du Sang, Lille, France. Sahlgrenska University Hospital, Center for Hematopoietic Cell Transplantation, Hematology Section, Goeteborg, Sweden. Campus Charité Mitte, Medizinische Klinik und Poliklinik II, m.S. Onkologie und Haematologie, Berlin, Germany. Ospedale di Niguarda Ca’ Granda, Hematology Dept., Milan, Italy. Hannover Medical University, Dept. of Transfusion Medicine, Hannover, Germany. Hospital San Maurizio, Dept. of Hematology - BMT Unit, Bolzano, Italy. University of Wales, College of Medicine, Dept. of Haematology, Cardiff, United Kingdom. Ospedale di Careggi, BMT Unit Department of Hematology, Florence, Italy. Roosevelt Hospital, Dept. of Hematology, nám.g.Svobudu 1, Banská_Bystrica, Slovakia. Grampian University Hospitals Trust, Aberdeen Royal Infirmary- Foresterhill, Dept. of Haematology, Aberdeen, United Kingdom. Bristol Royal Hospital for Children, Dept. of Paediatric Oncology/BMT, Bristol, United Kingdom. Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom. Heinrich Heine Universität, Klinik für Hämat, Onkol, Klin.Immun., Düsseldorf, Germany. Ospedale V. Cervello, Div. di Ematologia e Unità Trapianti, Palermo, Italy. Royal Liverpool University Hospital, Dept. of Haematology, Liverpool, United Kingdom. Helsinki University Central Hospital, Dept. of Medicine, Helsinki, Finland. IRCCS, Casa Sollievo della Sofferenza, Unit of Hematology and Bone Marrow Transplantation, San Giovanni Rotondo, Italy. Pesaro Hospital, Hematology & Transplant Center, Pesaro, Italy. Friedrich-Schiller-Universität Jena, Klinik f. Innere Medizin II, Jena, Germany. IRCCS Policlinico San Matteo, Pediatric Hematology-Oncology, Pavia, Italy. Wellington Blood & Cancer Center, Wellington Hospital, Wellington, New Zealand. Military Medical Academy, Clinic of Haematology, Belgrade, Serbia and Montenegro. VU University Medical Center, Dept. of Hematology (Br 250), Amsterdam, Netherlands. Manchester Royal Infirmary, Haematology, Manchester, United Kingdom. University Hospital Eppendorf, Bone Marrow Transplantation Center, Hamburg, Germany. Ankara University Faculty of Medicine, Dept. of Hematology, Adult Stem Cell Transplantation Unit, Ankara, Turkey. Evangelismos Hospital, Division of Hematology, BMT Unit, Athens, Greece. Hopital de Purpan, CHU Dept. Hematologie, Toulouse, France. Klinikum Nürnberg, 5. Medizinische Klinik, BMT-Unit, Nürnberg, Germany Shariati Hospital, Hematology-Oncology and BMT Research, Teheran, Iran. University Med. Center, Dept. of Hematology, Ljubljana, Slovenia. Hospital Covadonga, Hematology Dept., Oviedo, Spain. Universita degli Studi di Bari, Cattedra e Servizio di Ematologia, Azienda Policlinico Bari, Bari, Italy. CHRU, Service des Maladies du Sang, Angers, France. Hospital Universitario La Fe, Servicio de Hematologia, Valencia, Spain. Institut Gustave Roussy, BMT Unit, Hematology Division, Villejuif, France. CHR-CHU-Hopital de Hautepierre, Service d’Onco Hematologie, Strasbourg, France. Hopital d’Enfants, Unité de Transplantation Médullaire, Service de Méd. Infantile, Vandoeuvre les Nancy, France. Silesian Medical Academy, University Dept. of Haematology and BMT, Katowice, Poland. University of Münster, Dept. of Hematol./Oncol., Münster, Germany. Musgrove Park Hospital, (Somerset), Taunton, United Kingdom. Charles University Hospital, Dept. of Hematology/Oncology, Pilsen, Czech Republic. Clinica Puerta de Hierro, Servicio de Hematologia y Hemoterapia, Madrid, Spain. Umea University Hospital, Dept. of Internal Medicine, Umeå, Sweden. Hospital Morales Meseguer, C/ Marqués de los Velez s/n, Unidad de Trasplante de Médula Osea, Serv de Hematología y Oncología Médica, Murcia, Spain. Chaim Sheba Medical Center, Tel-Hashomer, Israel. L’Hospital Universitari de Bellvitge, Dept. Hematología Clinica, L’Hospitalet de Llobregat, Barcelona, Spain. Istanbul Tip Fakueltesi, Ic Hastaliklari. Hematoloji, Kemik iligi nakli ünitesi, Istanbul, Turkey. University of Naples, ‘Federico II’ Medical School, Division of Hematology, Naples, Italy. Hospital Virgen del Rocio, Servicio Andaluz de Salud, Sevilla, Spain. University of Saarland, University Hospital, Homburg, Germany. Unità Operativa Oncoematologia Pediatrica, Azienda Ospedaliera Universitaria Pisa, Pisa, Italy. S. Bortolo Hospital, Department of Hematology, Vicenza, Italy. Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m. S. Hämatologie/ Onkologie, Berlin, Germany. University of Freiburg, Dept. of Medicine Hematology, Oncology, Freiburg, Germany. Istituto Scientifico H.S. Raffaele, Hematology and BMT, Milan, Italy. Center Henri Becquerel, Hematology, Rouen, France. Central Clinical Hospital, The Medical University of Warsaw, Dept. of Hematology & Oncol, Warsaw, Poland. National Medical Center, Budapest, Hungary. St. László Hospital, Budapest, Hungary. Hospital No. 9, Minsk, Belarus.
|
Footnotes
|
|---|
* Other co-authors are listed in the Appendix. 
Authorship and Disclosures
LC, AG, EG , FF, RP, RW, EM, DB, AIA, JS, MS, NCG and VR: acquisition of data, revision and approval of the article; LF, in addition: design of the study, interpretation and drafting the article; ML:analysis of data. The authors reported no potential conflicts of interest.
Received for publication January 17, 2007.
Revision received January 7, 2008.
Accepted for publication January 30, 2008.
|
References
|
|---|
- Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Joint Accreditation Committee of the International Society for Cellular Therapy ISCT; European Group for Blood and Marrow Transplantation EBMT. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007;39:71-87.[CrossRef][ISI][Medline]
- Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979;300:1068-73.[Abstract]
- Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, et al. Identical-twin bone marrow transplant for leukaemia. Ann Intern Med 1994;120:646-52.[Abstract/Free Full Text]
- Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft versus leukaemia reactions after bone marrow transplantation. Blood 1990;75:555-62.[Abstract/Free Full Text]
- Barret AJ, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukaemia. The GVHD/GVL Working Committee of the International Bone Marrow Transplant Registry. Blood 2000;95:3323-7.[Abstract/Free Full Text]
- Adams KM, Holmberg LA, Leisenring W, Fefer A, Guthrie KA, Tylee TS, et al. Risk factors for syngeneic graft-versus-host disease after adult hematopoietic cell transplantation. Blood 2004;104:1894-7.[Abstract/Free Full Text]
- Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.[CrossRef][ISI][Medline]
- Fine JP, Gray RJ. A proportional hazards model for subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.[CrossRef][ISI]
- Mrozek K, Heinonen K, De la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukaemia. Semin Oncol 1997;24:17-31.[ISI][Medline]
- Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997;90:2978-86.[Abstract/Free Full Text]
- Reiffers J, Stoppa AM, Attal M, Michallet M, Marit G, Blaise D, et al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. Leukemia 1996;10:1874- 82.[ISI][Medline]
- Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004;22:4075-86.[Abstract/Free Full Text]
- Gahrton G, Svensson H, Björkstrand B, Apperley J, Carlson K, Cavo M, et al. Syngeneic transplantation in multiple myeloma: a case-matched comparison with autologous and allogeneic transplantation. The European Group for Blood and Marrow Transplant. Bone Marrow Transplant 1999;24:741-5.[CrossRef][ISI][Medline]
- Rappeport J, Mihm M, Reinherz E, Lopansri S, Parkman R. Acute graft versus host disease in recipients of bone marrow transplants from identical twin donors. Lancet 1997;2:717-20.
- Hood AF, Vogelsang GB, Black LP, Farmer ER, Santos GW. Acute graft vs host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987;123:745-50.[Abstract]
- Einsele H, Ehringer G, Schneider EM, Krüger GF, Vallbracht A, Dopfer R, et al. High frequency of graft versus host like syndromes following syngeneic bone marrow transplantation. Transplantation 1988;45:579-85.[ISI][Medline]
- Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. The ECOG; MRC/NCRI Adult Leukemia Working Party. Blood 2005;106:3760-7.[Abstract/Free Full Text]
- Jourdan E, Reiffers J, Stoppa AM, Sotto JJ, Attal M, Bouabdallaha R, et al. Outcome of adult patients with acute myeloid leukaemia who failed to achieve complete remission after one course of induction chemotherapy: a report from the BGMT Study Group. The BGMT Study Group. Leuk Lymphoma 2001;42:57-65.[CrossRef][ISI][Medline]
Related Article
-
Post-remission therapy in acute myeloid leukemia: what should I do now?
- William Blum
Haematologica 2008 93: 801-805.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
W. Blum
Post-remission therapy in acute myeloid leukemia: what should I do now?
Haematologica,
June 1, 2008;
93(6):
801 - 805.
[Full Text]
[PDF]
|
|
|
TOP
ABSTRACT
Introduction
